{
    "nctId": "NCT03921866",
    "briefTitle": "UK Ibrance Patient Program (IPP) Study",
    "officialTitle": "Observational Cohort Study of Patients With Hormone Receptor-positive Metastatic Breast Cancer Treated With Palbociclib (Ibrance(Registered)) as Part of the United Kingdom Ibrance (Registered) Patient Program (IPP); the Real Outcomes Ibrance (Registered) Study (ROIS)",
    "overallStatus": "COMPLETED",
    "conditions": "HR+/HER2- Locally Advanced, Metastatic Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 191,
    "primaryOutcomeMeasure": "Percentage of Participants According to Treatment Lines",
    "eligibilityCriteria": "Inclusion criteria:\n\nAll patients meeting the following eligibility criteria will be included in the study:\n\n* Patients enrolled into the IPP at one of the selected hospitals (see Annex 1 for IPP enrolment letter).\n* Patients who received \u22651 dose of palbociclib as part of the IPP at one of the selected sites.\n* For sites where data collection is performed by pH Associates, written informed consent will be required from living patients to access their medical records.\n* Patient aged \u226518 years old at enrollment into the IPP",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}